The MHRA is changing how the risks of antidepressants are communicated, after a review driven by patients and families who said the existing leaflets did not make two known risks clear enough: suicidal thoughts and behaviors, particularly early in treatment or after dose changes, and sexual dysfunction that can continue after the medicine is stopped.
Three measures follow. Patient information leaflets will carry a new boxed warning highlighting the suicidal thoughts risk and where to get help. A patient card, credit card sized in hard copy and available electronically in the interim, will reinforce the key messages at the point of dispensing. And the term post SSRI sexual dysfunction, the name patients themselves use, will be added to the leaflets of antidepressants associated with persistent sexual dysfunction. A fuller safety leaflet setting out benefits, risks and alternatives is being developed with health system partners and becomes available in 2027. Clinicians are advised to raise both risks when starting treatment or changing dose, and at the next review for existing patients.
The process matters as much as the content. A Commission on Human Medicines expert working group met from May 2024 to July 2025, heard directly from patients and bereaved families, and its recommendations were considered in September 2025. The final leaflet wording was user tested with a patient focus group convened with the Patients Association. A detailed public assessment report accompanies the update.
For manufacturers the direct cost is labeling and packaging change across a mature, mostly generic class. The commercial significance is wider: regulators rarely add boxed warnings to leaflets for drugs taken by millions without expecting prescribing conversations to change, and any shift in initiation or persistence rates in the UK will be visible in prescribing data within quarters. The explicit adoption of patient language for a contested adverse effect is also a precedent other agencies, including the FDA, will face questions about.